Subtype
Bladder Carcinoma
CI-CAN-00007316Explore in graph →
141 active trials7 approved drugs19 evidence items
Loading cancer entity…
Subtype
CI-CAN-00007316Explore in graph →
Clinical trials
332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06215976 | The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer | unknown | Phase 4 | 78 | Cairo UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03038321 |
| Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? |
| unknown |
| Phase 4 |
| 150 |
| Mansoura UniversityOTHER |
| 1 |
| May 23, 2017 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2024source: clinicaltrials